In the context of DCM, CRISPR could potentially correct pathogenic mutations (e.g., in the insulin signalling pathway, mitochondrial regulators, or fibrosis-related genes), offering a curative approach (Kambis and Mishra, 2023). The gene discussed is INS; the disease is familial dilated cardiomyopathy.